8min chapter

Oncotarget cover image

Dr. Blagosklonny’s Strategy: From Osimertinib to Preemptive Combinations

Oncotarget

CHAPTER

Exploring Osimertinib, Tackling Resistance, and Preemptive Combinations in Lung Cancer Treatment

The chapter explores the evolution of treatment for EGFR-mutated non-small cell lung cancer, highlighting the challenges with previous EGFR inhibitors and the promising role of Osimertinib as a third-generation TKI. It also discusses the concept of preemptive combinations to enhance treatment efficacy and address resistance mechanisms in NSCLC patients.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode